Head-to-head · two doors, two philosophies
Hims vs Ro: the commitment discount against the insurance navigator
Latest first-party read (September 17, 2026), from the open dataset. Hims & Hers (read September 17, 2026 at hims.com): tirzepatide — $448/mo all-in: $299 medication + $149/month membership (brand product; medication rises by dose); flags: membership stacked, rises with dose; dose policy rises with the dose; labs not advertised; pharmacies brand product; cancellation: not printed on the page read. semaglutide — $298/mo all-in: $149 medication + $149/month membership (brand product; medication rises by dose); flags: membership stacked, rises with dose; dose policy rises with the dose; labs not advertised; pharmacies brand product; cancellation: not printed on the page read. Ro Body (read September 17, 2026 at ro.co): tirzepatide — $448/mo all-in: $299 medication + $149/month membership (brand product; medication rises by dose); flags: membership stacked, rises with dose; dose policy rises with the dose; labs not advertised; pharmacies brand product; cancellation: the $39 start payment is refunded if not eligible. semaglutide — $298/mo all-in: $149 medication + $149/month membership (brand product; medication rises by dose); flags: membership stacked, rises with dose; dose policy rises with the dose; labs not advertised; pharmacies brand product; cancellation: the $39 start payment is refunded if not eligible. The file below records this site’s earlier, dated read; any figure it carries that the provider’s page no longer prints is kept as dated history and is not ranked. Dated pages, regenerated on every build: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
August 2026 correction: Hims no longer offers compounded tirzepatide (March 2026 settlement); its cash lane today is ~$175 flat semaglutide plus brand access. The coverage-vs-cash frame below survives; the molecule changed.
These two aren't really competing on price — they're competing on which problem you have. Hims sells a semaglutide cash rate (~$175 flat, Aug 2026; tirzepatide exited Mar 2026) — historically (~$165/month) priced to a twelve-month signature, a committed year landing near $1,980 [historical; Hims tirz lane closed 3/26]. Ro sells navigation: an insurance-first pathway whose whole bet is that a covered brand copay beats every cash number on the internet. Cash payers and covered payers are different species; this page sorts you first, then compares.
The cash laneHims
~$175/month flat semaglutide (Aug 2026; tirzepatide exited Mar 2026) — a real mid-market rate whose true price is the signature. Annualized: ~$1,980 [historical; Hims tirz lane closed 3/26]. Exit before term is where the fine print lives; read it before, not after. ON RECORD
The coverage laneRo
Insurance-first: prior-auth navigation toward covered brand medication, with self-pay routing as fallback. When PA clears, a brand copay can undercut every cash figure in our field — that's the entire product. Plan-dependent by definition. ON RECORD
The sorting questionYou
"Do I have commercial insurance that plausibly covers Zepbound or Wegovy?" Yes → run Ro's lane (or your own PA — the coverage test costs a phone call) with a 3–4 week deadline before paying anyone cash. No → Ro's core value evaporates and this becomes a cash-rate comparison.
The cash-rate verdictThe benchmark
As a pure cash rate, $175×12 (sema, 8/26) loses to the audited flat years — $1,668 tirzepatide, $1,428 semaglutide, dose-proof, no term lock. Hims' honest case is brand familiarity and platform polish; the arithmetic case belongs elsewhere.
The verdict, as a rule: insured shoppers test Ro's lane first with a deadline — a cleared PA beats everything, and a stalled one costs only weeks. Cash shoppers skip both stories: the commitment rate loses ~$300–$550/year to the audited flats while also costing exit freedom, and Ro without coverage is a navigator with nowhere to navigate. Standard footer: compounded product carries no FDA review; molecule fit is a clinician's call.
Hims — the committed rate ↗ Ro — test the coverage lane ↗ The audited flat benchmark ↗
Partner links carry sponsored tags; the sorting logic predates every link. How the money works.
Is Hims or Ro cheaper for GLP-1s?
Different lanes: Hims is a ~$175/month flat semaglutide cash rate (tirzepatide exited Mar 2026); historically a $165 12-month commitment (~$1,980 [historical; Hims tirz lane closed 3/26]/year); Ro's value is insurance navigation toward a covered brand copay, which — when PA clears — beats every cash price. Without coverage, both lose the cash math to the audited $1,428–$1,668 flat years.
Who should choose Ro?
Shoppers with commercial insurance that plausibly covers brand GLP-1s — its navigator model exists for exactly that conversion, and it's worth a deadlined 3–4 week test before paying cash anywhere.
What's the catch in Hims' price?
The signature: the rate is conditioned on a twelve-month term, so the honest price is the annual total and the exit terms — both worth reading in writing first.
More head-to-heads: NexLife vs Hims · NexLife vs Ro · NexLife vs ShedRx · Mochi vs Henry